Neuland Laboratories Ltd. (NEULANDLAB) Price & Analysis

Compare

4 Followers

NEULANDLAB Stock Chart & Stats

₹15265.60

₹591.15(4.14%)

At close: Jan 08 4:00 PM EST

₹15265.60

₹591.15(4.14%)

Day’s Range― - ―

52-Week Range₹10,060.00 - ₹19,748.40

Previous CloseN/A

Volume58.52K

Average Volume (3M)2.41K

Market Cap

₹159.19B

Enterprise Value₹161.49B

Total Cash (Recent Filing)₹1.80B

Total Debt (Recent Filing)₹2.65B

Price to Earnings (P/E)120.0

Beta0.89

Next Earnings

May 12, 2026

EPS Estimate

75.16

Next Dividend Ex-DateN/A

Dividend Yield0.08%

Share Statistics

EPS (TTM)37.00

Shares Outstanding12,829,889

10 Day Avg. Volume1,318

30 Day Avg. Volume2,408

Financial Highlights & Ratios

PEG Ratio-4.25

Price to Book (P/B)9.66

Price to Sales (P/S)9.98

P/FCF Ratio132.83

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)246.06

Revenue Forecast (FY)₹17.64B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA high equity ratio and prudent leverage give Neuland durable financial flexibility to fund capex, scale manufacturing, and support long-term contracts. This stable balance sheet reduces refinancing risk and underpins multi-year supply commitments in the API/CMS business.

Operating Cash GenerationSustained operating cash flow and multi-year free cash flow improvement indicate internal funding capacity for R&D, process development and capacity expansion. Reliable cash generation supports contract manufacturing scale-up and reduces dependence on external financing.

Revenue Growth & Margin TrendsMulti-year revenue expansion and improving gross margins signal stronger pricing power, manufacturing efficiency and portfolio mix improvement. These trends support sustainable EBITDA growth and competitiveness in the generics/API and custom manufacturing markets.

Bears Say

Earnings VolatilityA steep negative EPS growth rate points to material volatility in net income that can stem from margin swings, one-offs or pricing pressure. Persistent EPS volatility undermines earnings predictability and complicates reinvestment and dividend planning over the medium term.

Free Cash Flow VariabilityDeclines in free cash flow and year-to-year variability raise concerns about working capital swings or project timing. Variable FCF can constrain funding for capex, customer-driven scale-ups, and make execution of multi-year CMS projects more capital-sensitive.

Rising Debt TrendAn increasing absolute debt level, even with currently prudent ratios, elevates leverage risk if revenue or margins falter. Higher debt can limit financial flexibility for opportunistic investments or make the company more sensitive to interest rate and covenant pressures over the medium term.

Neuland Laboratories Ltd. News

Neuland Laboratories Reports Loss of Share Certificate by Investor

The latest announcement is out from Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ). Neuland Laboratories Ltd. has informed the...

8d ago

Neuland Labs Schedules Non-Deal Roadshows in Hong Kong and Singapore

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) has shared an announcement. Neuland Laboratories has announced a schedule of upcoming...

17d ago

Neuland Laboratories Opens Special Window for Re-lodgement of Physical Share Transfers

An announcement from Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) is now available. Neuland Laboratories Ltd. has notified the...

3M ago

Neuland Laboratories Schedules Q2 FY26 Earnings Call

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) just unveiled an update. Neuland Laboratories Limited has scheduled an earnings call...

5M ago

Neuland Laboratories Opens Special Window for Share Transfer Requests

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) just unveiled an announcement. Neuland Laboratories Limited has announced a special window...

5M ago

Neuland Laboratories Announces Executive Restructuring via Postal Ballot

An announcement from Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) is now available. Neuland Laboratories Ltd. has announced a...

5M ago

Neuland Laboratories Issues Corrigendum to Postal Ballot Notice

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) has issued an announcement. Neuland Laboratories Limited has announced a newspaper advertisement...

6M ago

Neuland Laboratories Opens Special Window for Physical Share Transfers

Neuland Laboratories Ltd. ( ($IN:NEULANDLAB) ) has issued an announcement. Neuland Laboratories Ltd. has announced a special window...

7M ago

NEULANDLAB FAQ

What was Neuland Laboratories Ltd.’s price range in the past 12 months?

Neuland Laboratories Ltd. lowest stock price was ₹10060.00 and its highest was ₹19748.40 in the past 12 months.

What is Neuland Laboratories Ltd.’s market cap?

Neuland Laboratories Ltd.’s market cap is ₹159.19B.

When is Neuland Laboratories Ltd.’s upcoming earnings report date?

Neuland Laboratories Ltd.’s upcoming earnings report date is May 12, 2026 which is in 53 days.

How were Neuland Laboratories Ltd.’s earnings last quarter?

Neuland Laboratories Ltd. released its earnings results on Feb 09, 2026. The company reported ₹37 earnings per share for the quarter, missing the consensus estimate of ₹56.52 by -₹19.52.

Is Neuland Laboratories Ltd. overvalued?

According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neuland Laboratories Ltd. pay dividends?

Neuland Laboratories Ltd. pays a Annually dividend of ₹12 which represents an annual dividend yield of 0.08%. See more information on Neuland Laboratories Ltd. dividends here

What is Neuland Laboratories Ltd.’s EPS estimate?

Neuland Laboratories Ltd.’s EPS estimate is 75.16.

How many shares outstanding does Neuland Laboratories Ltd. have?

Neuland Laboratories Ltd. has 12,829,889 shares outstanding.

What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?

Neuland Laboratories Ltd. reported an EPS of ₹37 in its last earnings report, missing expectations of ₹56.52. Following the earnings report the stock price went up 6.856%.

Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:NEULANDLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Neuland Laboratories Ltd.

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.